Arcus Biosciences: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) reported its Q3 earnings, beating estimated earnings by 17.54% with an EPS of $-0.94 versus an estimate of $-1.14. However, revenue was down $1.58 million from the same period last year. Last quarter, the company missed on EPS by $0.04, which was followed by a 1.26% increase in the share price the next day.
November 07, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences beat Q3 earnings estimates but reported a decrease in revenue compared to the same period last year. The company's past performance shows a share price increase following a missed EPS estimate.
Arcus Biosciences beat earnings estimates, which is generally a positive signal for investors. However, the decrease in revenue compared to the same period last year might offset this positive impact. The company's past performance shows that even when it missed EPS estimates, the share price increased the next day, indicating that investors might have confidence in the company's long-term prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100